NEW YORK (Reuters) - Mylan NV (MYL.O) said on Wednesday its fourth-quarter earnings fell due to declining revenue from its EpiPen emergency allergy injector and weak U.S. prices for generic drugs.
The drugmaker reported net income of $244.3 million, or 46 cents a share, in the quarter, down from $417.5 million, or 78 cents a share, last year.
Excluding one-time items, the company said it earned $1.43 a share. Analysts on average were expecting $1.41, according to Thomson Reuters I/B/E/S.
Revenue in the quarter fell 1 percent to $3.24 billion, coming in below the average analyst expectation of $3.3 billion.
Mylan forecast adjusted earnings per share in the range of $5.20 to $5.60 for 2018, in line with analyst estimates.
Reporting by Michael Erman; Editing by Chris Reese and Tom Brown